Company Overview
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc
Why Investors Should Care
Generates a return on equity of 23.5%, reflecting efficient use of shareholder capital.
Trades at a P/E of 0.6, below the sector median of 24.8.
Carries low leverage with a debt-to-equity ratio of 0.09.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -57.1%.
- 5-Year Trend Long-term compounding — revenue CAGR -36.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -36.00% |
| 1 Year: | -57.10% |
Stock Price Performance
| 1 Year: | -8.93% |
| 6 Months: | -21.75% |
| 3 Months: | -10.71% |
| 1 Month: | +14.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.01 · Neutral
P/E of 0.57 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 23.5%.
- Generates positive free cash flow.
CONS
- Revenue declined at -36.0% CAGR over 5 years.
- Trading 35.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IBO Impact BioMedical Inc. PHARMA | 0.50 | 0.57 | $53.91M | 0.00% | -26.36% | 23.46% | -36.00% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.00K | - | - | - | - | - | - | - | - | 7.00K | 18.00K | 7.00K |
| Operating Income | -750.00K | -889.00K | -803.00K | -1.01M | -1.08M | -771.00K | -626.00K | -1.13M | -1.01M | -1.15M | -948.00K | -2.29M |
| Net Income | -799.00K | -2.24M | -849.00K | -1.12M | -1.18M | -962.00K | -889.00K | 4.25M | -1.27M | -14.35M | -1.47M | -2.29M |
| Diluted EPS | 0.00 | -0.03 | -0.01 | -0.02 | -0.02 | -0.10 | -0.09 | 0.06 | -0.11 | -1.18 | -0.12 | -0.02 |
| R&D Expense | 206.00K | 330.00K | 179.00K | 266.00K | 357.00K | 183.00K | 121.00K | 82.00K | 103.00K | 75.00K | 52.00K | 46.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 50.00K | - | - | 32.00K |
| Operating Income | -3.40M | -4.03M | -28.75M | -4.28M |
| Net Income | -7.25M | -4.34M | -24.71M | -11.84M |
| Diluted EPS | -0.10 | -0.07 | -2.30 | -0.38 |
| R&D Expense | 1.23M | 1.69M | 278.00K | 340.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 46.50M | 44.63M | 20.29M | 17.41M |
| Total Equity | 39.92M | 29.56M | 25.22M | 4.26M | 12.61M |
| Cash & Equivalents | - | 2.00K | 1.00K | 2.00M | 3.00K |
| Total Liabilities | - | 13.83M | 16.37M | 13.05M | 1.85M |
| Current Liabilities | - | 10.59M | 13.14M | 9.79M | 1.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -2.24M | -2.85M | -2.85M | -1.89M |
| Investing Cash Flow | -349.00K | -15.00K | 2.00K | 3.00K |
| Financing Cash Flow | 2.55M | 2.87M | 4.85M | -109.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -6,808.0% | - | - | -13,381.2% |
| Net Margin % | -14,510.0% | - | - | -36,993.8% |
| ROE % | -24.5% | -17.2% | -580.1% | -93.9% |
| ROCE % | -9.5% | -12.8% | -273.7% | -26.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 1.10% | 1.19M | $699.25K |
| 2 | Vanguard Capital Management LLC | 0.75% | 808.69K | $477.13K |
| 3 | State Street Corporation | 0.56% | 607.90K | $358.66K |
| 4 | Vanguard Fiduciary Trust Co | 0.55% | 589.43K | $347.76K |
| 5 | Blackrock Inc. | 0.24% | 259.95K | $153.37K |
| 6 | Northern Trust Corporation | 0.22% | 235.47K | $138.93K |
| 7 | Citadel Advisors Llc | 0.05% | 49.57K | $29.24K |
| 8 | Vanguard Global Advisers, LLC | 0.03% | 32.20K | $19.00K |
| 9 | Jane Street Group, LLC | 0.02% | 24.53K | $14.47K |
| 10 | Two Sigma Investments, LP | 0.02% | 17.19K | $10.14K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IBO
IBO Stock Spikes Pre-Market: Retail Traders Pile Into Biotech Penny Stock After Merger Update - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSzhVR05aTkpvaU1tVlA5d1F1NVdidENreU1zMlBKZ08yTTdlMVF5N212cXV4MHQzUEJkMU9BdF9Ld3NpTXBVQVVNLVRmWjIySTgzQlJDR1g4RkNnUGxEejRfUjd2djFLQzZXYXp0aEpzSWZsYTl1UER6YU1hMjZaVXVGQlNaejYzMkYyTn…
IBO - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTFBMdGZxZXVLYzRRcVRJNnhuUUlVUU9OMnVjVnpwQjFOT3NSYnNHaGd2RWNJV3FrSWZkem8tT1lZMW41MzM4?oc=5" target="_blank">IBO</a> <font color="#6f6f6f">Finviz</font>…
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in July 2026 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxORmRaa0RqY0lHbnh4VHpjZEFiUlEzSFFqaUNIbHBfWU1TaUJJSkRVX0N2Rm0wZFJEYXpHaWRVNVRsTEJwR1BDblZrU2t2UTlCUzMzTXlCZUNlT2Z1ek1QczhZUXZBOXR3WFlGaFNSSE9uRGNkNHJNc0ZPZkJYVzBYRjhSXzVzc2FKeUIyNF…
Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue - Barchart.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxON3gtUXJGX3owWlBuZGQwZV9DUFprSjNTQ0J3cUxCekFXU295NThHel8xRFJsdXJFZGlXaWhQNkVCbl9HY2N1ZGxRY2NVZ2ZjOEt2dnFqR3hueHloTXNvQzlIRXNPUWNmVGdXRmpKSHQ2cDlBaVpFQmQzSEhkcUdXS3JkR2g5S2NfRkhUcF…
Impact (IBO) Shares: Slides 4.47% to $0.45 in the Current Update; Price Context: Traders Can Monitor the $0.43-$0.47 Range in Latest Trading - Trend Continuation Trade - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMi_AFBVV95cUxPQm0yLVpxVVVOMEoxM19FekEzYVdQNDk3alJScXRyZFhSVlhIbnlMc0lObmFadHpENVd0ejB1NU9icXJXdk9VU20tcXd3cWhaZ3E0WllkMHpQazRZOVhtNlZrbmNPR2JLeGhjSHB3ODN1N1pCMFZEY21idDhOWjZhMlN5LXJrR1FOYjhpRm…
Announcement - In relation to the matter of IBO Technology Company Limited (In Liquidation) (incorporated in the Cayman Islands with limited liability) (Stock Code: 2708) Cancellation of listing - hkex.com.hk
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxObDRKaUdvVjNWazZ4VUNxV05fb1BUbnFWV2hmcHZMVWVQS1c3RklXQjBkWDRjYkp1cmY4cVJObFZxSG03WFE3alVjaWpWb1p0REpzZUNlSEVYaHp4RmtnN3hMdmFjRlZVVU8tbnRDMEUyRmJib3JkcHhxUHVJZ3daQmJoWUJjeXM?oc=5" …
IBO — Frequently Asked Questions
What is the current share price of Impact BioMedical Inc. (IBO)?
As of 2026-09-19 21:16 PDT, Impact BioMedical Inc. (IBO) trades at $0.50 on NYSE American. Its 52-week range is $0.40 to $0.78.
What is the market capitalisation of IBO?
Impact BioMedical Inc. (IBO) has a market capitalisation of $53.91M on NYSE American.
What is the P/E ratio of IBO?
IBO trades at a trailing price-to-earnings (P/E) ratio of 0.57. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.90.
What is the return on equity (ROE) of IBO?
IBO has a return on equity (ROE) of 23.46%. Its return on capital employed (ROCE) is -26.36%.
Is IBO a good stock to buy?
This page provides a data-driven analysis of Impact BioMedical Inc. (IBO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.